#Exome Sequencing

[pathologylab]

#G2M offers a wide range of comprehensive as well as targeted #NGS-based #clinical_panels which have been rigorously designed and engineered for achieving uniform depth coverage and precision in #diagnosis for germline and somatic #diseases. Our NGS #panels cater to various therapy segments like #Oncology, Infectious diseases, #Mother and #Child_care, targeted disorders like cardiovascular, and neurological, as well as #pharmacogenomics etc. With cost effective and easy to use assay workflows, we empower #researchers and clinicians to uncover critical genomic insights efficiently with a goal of making #Genetic_testing accessible to all.

Contact us at social@genes2me.com or +91-8800821778 if you need any further assistance!

Visit our website for more information: https://www.genes2me.com/next-generation-sequencing-clinical-panels

#ngspanels #genes2me #cinicalpanel #cancers #testing #exome #sequencing #nextgenerationsequencing #blood #panel #Genomics #PrecisionMedicine

[maisha-online]

The Essential Role of Cylicins in Sperm Development and Fertility

Sperm development, known as spermiogenesis, is a complex process involving various stages and intricate structural changes. Recent research has shed light on the crucial role of Cylicins in spermiogenesis and male fertility in both mice and humans. Cylicins, specifically Cylicin 1 (Cylc1) and Cylicin 2 (Cylc2), are essential components of the perinuclear theca (PT), a critical part of the sperm…

[harshnews]

Whole Exome Sequencing Market Size, Share, Key Drivers, Trends, Challenges and Competitive Analysis

"Global Whole Exome Sequencing Market – Industry Trends and Forecast to 2029

Global Whole Exome Sequencing Market, By Component (Second-Generation Sequencing and Third-Generation Sequencing), Product and Service (Systems, Kits, and Services), Application (Drug Discovery and Development, Agriculture & Animal Research, Diagnostics, Personalized Medicine, and Others), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals and Clinics, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others), Industry Trends and Forecast to 2029.

Access Full 350 Pages PDF Report @

**Segments**

- **Product Type**: The whole exome sequencing market can be segmented based on product type into kits, reagents, and sequencing services. Kits and reagents are essential components for conducting whole exome sequencing procedures, while sequencing services are offered by specialized laboratories for those researchers who prefer outsourcing this aspect of the process. The increasing demand for convenient and cost-effective solutions in the field of genomics research is driving the growth of all these segments within the market.

- **Application**: In terms of application, the market can be segmented into diagnostics, drug discovery, personalized medicine, agriculture, and others. Whole exome sequencing plays a crucial role in the diagnosis of genetic disorders, identification of potential drug targets, personalized treatment strategies, and enhancing agricultural productivity through genetic modification. The versatility of whole exome sequencing applications positions it as a valuable tool across various sectors, thereby contributing to the market's expansion.

- **End User**: The end-user segment includes academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinical laboratories, and others. Academic and research institutes are significant contributors to the demand for whole exome sequencing technologies owing to their focus on advancing genomic research. Pharmaceutical and biotechnology companies rely on these technologies for drug development, while hospitals and clinical laboratories utilize them for diagnostic purposes. The diverse end-user base reflects the broad utility of whole exome sequencing solutions in different settings.

**Market Players**

- Illumina, Inc. - Thermo Fisher Scientific Inc. - Agilent Technologies, Inc. - PerkinElmer Inc. - Eurofins Scientific - Macrogen, Inc. - GENEWIZ - Otogenetics Corporation - BGI - F. Hoffmann-La Roche Ltd - QIAGEN - GATC Biotech AG - Novogene Corporation

The global whole exome sequencing market is dynamic and competitive, with key players continuously focusing on research and development initiatives to introduce innovative products and expand their market presence. Companies suchThe global whole exome sequencing market is witnessing robust growth driven by various factors such as the increasing prevalence of genetic disorders, rising adoption of personalized medicine, advancements in genomic technologies, and growing investments in research and development activities. The market segmentation based on product type, applications, and end-users offers a comprehensive view of the diverse opportunities and challenges present in this domain.

The product type segmentation of the whole exome sequencing market into kits, reagents, and sequencing services highlights the essential components required for conducting sequencing procedures. Kits and reagents play a critical role in sample preparation, library construction, and sequencing processes, thereby driving the demand for these consumables. On the other hand, sequencing services cater to researchers and organizations looking to outsource their sequencing needs, providing convenience and expertise in conducting complex genomic analyses. The market for product types is expected to grow significantly as researchers seek more efficient and cost-effective solutions for their genomic studies.

In terms of applications, the whole exome sequencing market is segmented into diagnostics, drug discovery, personalized medicine, agriculture, and others. The diagnostic segment holds a prominent share due to the increasing use of whole exome sequencing in identifying genetic variations associated with various diseases and disorders. In drug discovery, researchers leverage exome sequencing data to identify novel drug targets and develop more effective therapies. Personalized medicine is another key application area where whole exome sequencing helps in tailoring treatment regimens based on individual genetic profiles. The agriculture segment is also witnessing growth as genetic modifications are being used to enhance crop yield, pest resistance, and overall agricultural productivity. The broad spectrum of applications underscores the versatility and relevance of whole exome sequencing across different sectors.

The end-user segment of the whole exome sequencing market encompasses academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinical laboratories, and others. Academic and research institutes are at the forefront of genomic research, driving the demand for advanced sequencing technologies to further scientific knowledge and discoveries. Pharmaceutical and biotechnology companies rely on exome sequencing for target**Segments**

- **Product Type**: The whole exome sequencing market is segmented into kits, reagents, and sequencing services. Kits and reagents are crucial for performing sequencing procedures, while sequencing services are offered by specialized labs for outsourcing. The demand for cost-effective solutions in genomics research is propelling growth in these segments.

- **Application**: The market is divided into diagnostics, drug discovery, personalized medicine, agriculture, and other areas. Whole exome sequencing aids in diagnosing genetic disorders, finding drug targets, tailoring treatments, and improving agricultural processes. Its versatility positions it as a valuable tool in various sectors.

- **End User**: The end-user segment involves academic institutions, pharmaceutical companies, hospitals, and other organizations. Academic institutes drive demand for sequencing tech in genomic research. Pharmaceutical firms utilize it for drug development, while hospitals use it for diagnostics. The diverse user base showcases the broad utility of whole exome sequencing solutions.

By delving into the market players involved in the global whole exome sequencing field, key companies such as Illumina, Inc., Thermo Fisher Scientific Inc., and Agilent Technologies, Inc., are continuously investing in research and development efforts to introduce innovative products and strengthen their market presence. These players, alongside others like Eurofins Scientific and Novogene Corporation, contribute to the competitive landscape of the market. Factors such as the rising incidence of genetic disorders, the adoption of personalized medicine, technological advancements in genomics, and increased R&D investments are propelling the

Key points covered in the report: -

The pivotal aspect considered in the global Whole Exome Sequencing Market report consists of the major competitors functioning in the global market.

The report includes profiles of companies with prominent positions in the global market.

The sales, corporate strategies and technical capabilities of key manufacturers are also mentioned in the report.

The driving factors for the growth of the global Whole Exome Sequencing Market are thoroughly explained along with in-depth descriptions of the industry end users.

The report also elucidates important application segments of the global market to readers/users.

This report performs a SWOT analysis of the market. In the final section, the report recalls the sentiments and perspectives of industry-prepared and trained experts.

The experts also evaluate the export/import policies that might propel the growth of the Global Whole Exome Sequencing Market.

The Global Whole Exome Sequencing Market report provides valuable information for policymakers, investors, stakeholders, service providers, producers, suppliers, and organizations operating in the industry and looking to purchase this research document.

What to Expect from the Report, a 7-Pointer Guide

The Whole Exome Sequencing Market report dives into the holistic Strategy and Innovation for this market ecosystem

The Whole Exome Sequencing Market report keenly isolates and upholds notable prominent market drivers and barriers

The Whole Exome Sequencing Market report sets clarity in identifying technological standardization as well as the regulatory

framework, besides significantly assessing various implementation models besides evaluation of numerous use cases

The Whole Exome Sequencing Market report is also a rich repository of crucial information across the industry, highlighting details on novel investments as well as stakeholders and relevant contributors and market participants.

A through market analytical survey and forecast references through the forecast tenure, encapsulating details on historical developments, concurrent events as well as future growth probability

Browse Trending Reports:

Threat Detection Systems Market Pipe Coating Market Fragrance Fixatives Market Mobile Campaign Management Platform Market Menstrual Cramps Treatment Market Roof Insulation Market Mobile Robotics Market Varnish Makers Market Urinary Incontinence Market Treatment Resistant Depression Market Robotic Prosthetics Market Neutropenia Market Polycystic Kidney Disease Adpkd Market Grain Analysis Market Solid State Solar Cell Market Panel Mount Industrial Display Market Automotive Mini Led Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[chetanagblog]

The Whole Exome Sequencing Market size was valued at USD 1.6 Billion in 2022 and the total revenue is expected to grow at a CAGR of 21.06 % from 2023 to 2029, reaching nearly USD 6.1 Billion.

[sports9885]

Data Bridge Market Research analyses that the whole genome and exome sequencing market, which was USD 1,099.22 million in 2022, is likely to reach USD 4,719.86 million by 2030 and is expected to undergo a CAGR of 21.20% during the forecast period. This indicates that the market value. “Hospitals and Clinics” dominate the end-user segment of the whole genome and exome sequencing market due to the growing demand for products. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

[dbmrmarketnews]

https://www.databridgemarketresearch.com/reports/global-whole-exome-sequencing-market

[shivt123]

North America Whole Exome Sequencing Market – Industry Trends and Forecast to 2029

[horsesource]

Ian's mom had exome sequencing done and was telling me the other day about how she feels a sense of relief knowing the "cause" etc etc and I'm just sitting like mmmmhm...even though, lady, said genetic difference is not a sentence for autism, the majority of the population diagnosed with said genetic difference are not diagnosed with autism..I am not blaming her for her son's autism, I mean, if I was gonna go down that line I'd thank her for her son's autism, I'm glad to have met her son and his autism, but like, when it comes to him pretty much doing the same thing every day, lady, when I try to do anything out of the ordinary with him in your presence you shit your pants. You shit your pants when he sneezes! I feel like if there's a gene to blame here it's gotta be the neurotypical shitting your pants when anything genuinely socially exploratory happens one

[bpod-bpod]

Malignant Evolution

Multi-pronged (whole-exome sequencing, RNA sequencing, and Imaging Mass Cytometry) approach characterises at the single-cell level the heterogeneity of upper tract urothelial carcinoma – cancers arising in the ureter and the kidney's 'pelvis' – from primary to metastatic

Read the published research article here

Image from work by Kentaro Ohara and colleagues

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA

Image originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)

Published in Nature Communications, March 2024

You can also follow BPoD on Instagram, Twitter and Facebook

[pathologylab]

G2M's #ClinicalExomeSequencing (CES) panel is rigorously engineered to sequence hard-to-capture regions such as homologous regions and repetitive sequences, which often pose challenges in #sequencing and data analysis. This panel offers detailed genomic profiling of various genetic diseases, covering a wide range of target regions like the whole coding sequence, mitochondrial genes, and hotspots such as splice junctions. The #G2M CES panel is compatible with all the commonly available #NGS platforms on the market. Additionally, this panel is complemented with a powerful data analysis platform called "Cliseq Interpreter," which is cloud-based #software for handling complex NGS data #analysis and interpretation.

To know more about these #NGSPanels, contact us at social@gmail.com or call us +91 8800821778.

Visit our website for more information: https://www.genes2me.com/next-generation-sequencing-clinical-panels/Clinical-Exome-Sequencing

#clinicalexome #ces #genes2me #nextgenerationsequencing #geneticdisease #software #panel #assays

[weakfleshwillingsoul]

Sudden driving thrill to read as many scientific articles as possible on cancer exome sequencing ...

[pennylunfersqueak]

I have finally recieved an official diagnosis!!!

I have, as predicted, Classical Ehlers-Danlos Syndrome. Specifically, a pathogenic variant of the COL5A1 gene, which is responsible for pro-alpha1(V) chain, a component of type V collagen. This type of collagen regulates the width of fibrils which are made of type I collagen. Therefore my fibrils are disorganised and larger than they should be, which weakens all connective tissues in my body.

Very exciting!!!!

ALSO

I should be able to recieve my own FASTA file with my own sequenced exome!!!!! Isn’t that super neat???

[bishiglomper]

After this whole trouble with drawing that darn foot I'm like. I need to practice. Do some ref studies and stuff. Find some krita tutorials because I'm still barely using it. (I'm still not sure how to do basic artisty functions.) I need to figure out how to color

Especially alastor hair because thats always what gets me, its so fuckin weird. I used to be able to color but I can't figure out how to make my usual method work with that fuckass bob istg

But then I look at the shit I've posted lately and it's like ...

... who am I kidding. I'm not gonna do the extra side quests. I only go back to drawing once in a blue moon (usually when I have a new favorite blorbo) I haven't seriously had fun with it for over a decade.

I don't have the constitution to draw every day. Here I am looking at peoples commissions info trying to figure out how would price mine and then I realize.

Oh.

Yeah, I can't do that.

I don't know what came over me, thinking I could like officially take requests 🙄 meanwhile im.over here flippin DYING just trying to get my new favorite project posted. When it's not even done. Just at a stopping point.

When I did that Niffty one I remember just trying to make it. The whole last quarter was me mentally chanting "just a little longer, just a little more" I didn't get to all the things I wanted, I just wanted it posted. Even if I don't get many notes I still need the instant gratification/dopamine fix of just getting it up there.

Le sigh.

Just frustrated with being physically pained by trying to do literally anything that brings me joy.

I mean being able to do some chores would be nice, but I'm salty about not being able to do a damn fun thing either.

Fun things are easier to find the willpower to push through. It produces the dopamine which in turn fuels it. But by God the backlash is horrible.

Literally just sitting at the desk drawing fucks me up so bad. It fucks my whole arm. It's stiff and tebdonitisy and I can't lift it for like 3 days. And my blister that's constantly there where the pen sits on. I gotta wear a double bandage for a cushion which makes it tolerable. The chair isn't comfortable. I hold my breath constantly. Which I just do when I'm in discomfort. I was super aware of it today..

And as soon as I exit hyperfocus i get hit with the fibro which feels like I'm bring vibrated on a molecular level at a frequency like an opera singer trying to break glass. But on my nervous system. Just this internal shiiiiiiing

It's awful

Not depressed over it but definitely disheartened. Frustrated. Annoyed.

I'm gonna ask my doctor if I can get genetic testing maybe if we can root around in there i could at least get some validation.

A friend who found their EDS diagnosis through genetic testing saidthy had an exome sequencing done

Sounded like I don't need to be looking for anything specific but it can tell me if I have certain things. Like heart disease or something. Im wondering if that weird test the heart doc did was a genetic thing.

Google said whole exome sequencing was good for finding originating deformities and syndromes and the like. I was born with a syndrome/ a collection of things that were enough to tick the box. So I should definitely have something pop up.

I'm hoping I can use that as a foot in the door and maybe my insurance will pay for it. 👀

[autism-unfiltered]

Can autism run in the family? As in can it be inherited and not just random?

Hello,

Yes, autism does seem to have a genetic component and can often run in families. Multiple scientific studies have found a higher concordance rate of autism in identical twins compared to fraternal twins, indicating a genetic influence. A large study published in JAMA Psychiatry in 2019 found that approximately 80% of the risk for autism comes from inherited genetic factors [1].

However, it's important to remember that autism is likely caused by a complex interplay of genetic and environmental factors. Even in cases of identical twins, one twin can be autistic while the other is not, which suggests that environmental factors also play a role.

Additionally, while autism can be inherited, it doesn't mean it will be. Having a family member with autism increases the chances, but it doesn't guarantee an autism diagnosis.

There isn't a single "autism gene". Rather, research indicates that many different genes may be involved. Some studies have identified over 100 genes associated with an increased risk of autism [2].

Please keep in mind that this is a simplification of a very complex topic, and ongoing research continues to increase our understanding of autism's causes.

For further reading, here are the sources I mentioned:

Association of Genetic and Environmental Factors With Autism in a 5-Country Cohort. JAMA Psychiatry, 76(10), 1035–1043.

Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell, 180(3), 568–584.e23.

Thank you for your question, it's an important one. Keep the questions coming!

[jcrmhscasereports]

 HEREDITARY FORM OF EPILEPSY ASSOCIATED WITH PYRIDOXAMINE 5'-PHOSPHATE OXIDASE DEFICIENCY IN A CHILD by Plotnikova I.A in Journal of Clinical Case Reports Medical Images and Health Sciences

SUMMARY

The article presents a clinical case of focal epilepsy with a status course of seizures associated with a genetic mutation in exon 1 of the PNPO gene, which led to pyridoxamine-5'-phosphate oxidase deficiency. The diagnosis was made late due to the misinterpretation of symptoms, which complicated the course of the disease. Despite the fact that the first symptoms in the form of seizures appeared at the age of 1 month, only at the age of 5 the diagnosis was verified by doing targeted DNA sequencing. At the moment, the patient is receiving substitution therapy in the form of pyridoxal phosphate 300 mg/day, which enabled unstable clinical remission. Right now, it is impossible to achieve complete control over the convulsive syndrome without a strict diet: dairy-free, meat-free, egg-free and low-protein fat-free food. Currently, further search for treatment methods continues to improve the patient's quality of life and ensure stable remission. A detailed analysis was given for further genetic verification based on the amino acid profile of the patient, and the rehabilitation potential was determined based on topical neuropsychological diagnostics performed on a non-verbal child.

Key words: focal epilepsy; Pyridoxal 5′-phosphate; vitamin B6; PNPO; vitamin B6-dependent epilepsy, neuropsychological diagnostics.

INTRODUCTION

Vitamin B6-dependent epilepsies are aheterogeneous group of autosomal recessive diseases that are caused by mutations of five different genes involved in vitamin B6 metabolism [1]. Vitamin B6 is present in many forms in the human diet, but only pyridoxal-5 -phosphate (PLP) plays a vital role in the metabolism of a number of neurotransmitters, especially the inhibitory mediator gamma-aminobutyric acid. Code errors leading to a lack of pyridoxal-5'-phosphate manifest as B6-dependent epilepsy, including pyridoxamine-5-phosphate oxidase (PNPO) deficiency, which affects the synthesis and recycling of pyridoxal-5'-phosphate [2,3]. Neonatal manifestation in the form of acute encephalopathy with biphasic epileptic seizures (or status epilepticus) is the main symptom of the disease. The first phase (early attacks) is accompanied by fever and a temporary recovery of consciousness and the development; the second phase is a global cognitive dysfunction (late attacks).

Resistance to traditional antiepileptic therapy requires patient's lifelong treatment by pharmacological doses of vitamin B6 in the form of pyridoxine (PN) or a biologically active form of pyridoxal-5’-phosphate [1,4].

Case reports of PLP deficiency, verified not only clinically, but also by exome sequencing, are quite rare as well as the methods for studying molecular markers of alpha-aminoadipic semialdehyde and pipecolic acid in body fluids [5–7]. The complexity of diagnosis is caused by multiple disorders in newborns, especially in case of a slow and incomplete response to pyridoxine [8].

Recent studies have shown that the main enzyme defect in pyridoxine-dependent epilepsy is caused by alpha-aminoadipic acid semialdehyde dehydrogenase in the pathway of cerebral lysine degradation. The accumulating compound, alpha-aminoadipine semialdehyde (alpha-AASA), is in equilibrium with delta-1-piperidine-6-carboxylate (P6C). P6C inactivates pyridoxal-5’-phosphate, causing severe cerebral insufficiency. Although treatment of pyridoxal 5'-phosphate deficiency can successfully control seizures, most patients develop some degree of disability, regardless of early diagnosis and treatment. Very few patients with normal intelligence have been reported [7].

Objective: to analyze the course of epilepsy with pyridoxamin-5’-phosphate oxidase deficiency in an 8-year-old patient with diagnosis verification by clinical exome sequencing.

MATERIALS AND METHODS OF RESEARCH.

The analysis of primary medical documentation from 2013 to 2021 of a patient born in 2013 was performed. We reviewed the materials on the topic using PubMed search engines for the period 2014-2021, correlation of literature data with a specific clinical case.

RESEARCH RESULTS AND THEIR DISCUSSION.

A clinical case

Girl, 8 years old, was born from IV pregnancy of a woman with a burdened obstetric history. At the age of 1 month, tonic-clonic convulsions were first noted during sleep: gaze adversion to the left, lasting 30 seconds - 1 minute; afterwards there was up to 4 seizures per day, daily. At the age of 1 year, she was hospitalized 4 times on an emergency basis for convulsive seizures. The child was observed by a neurologist-epileptologist with a diagnosis of perinatal damage to the central nervous system, recovery period. Valproic acid was prescribed at a dosage of 50 mg/kg per day, oxcarbazepine 300 mg/day, without an effect of therapy. At the age of 2 years, she was hospitalized three times in the intensive care unit due to the status course of an epileptic seizure with a rise in temperature to febrile numbers. Neurological diagnosis at that time was: symptomatic epilepsy with complex partial seizures, status course of generalized convulsive seizures. On electroencephalography (EEG): moderate diffuse changes in the bioelectric activity (BEA) of the brain in a disorganized type. The patient's condition worsened. At the age of 3 years, she was observed in the State Autonomous Healthcare Institution of the Sverdlovsk Region "Children's City Clinical Hospital No. 9, Yekaterinburg" with the same diagnosis; the dose of oxcarbazepine was increased to 500 mg/day, valproic acid to 300 mg/day with no significant clinical effect. At the age of 4 years, she was hospitalized three times in the intensive care unit about epileptic seizures, without the effect of anticonvulsant therapy. Concomitant diseases at age 4 were: severe osteoporosis of the visible parts of the skeleton; pathological compression fracture of the body Th11; hepatomegaly; moderate expansion of the common hepatic, common bile ducts; enlargement of the gallbladder; a pronounced increase in the size of the kidneys, pancreas; diffuse changes in the parenchyma of the kidneys, a single cyst of the right kidney; unspecified form of caries; chronic gingivitis. Computed tomography of the abdominal aorta and its branches showed no evidence of hepatic artery stenosis. Autonomic dysfunction of the sinus node was noted: sinus arrhythmia with episodes of bradycardia. There were also small anomalies in the development of the heart: a functioning foramen ovale, additional chords of the cavity of the left ventricle.

DNA sequencing was carried out in 2017. Genetic mutations that were identified are described in patients with epilepsy associated with pyridoxamine 5'-phosphate oxidase deficiency and, based on the totality of information, regarded as pathogenic - a mutation in exon 1 of the PNPO gene (chr17: 46019139A> T, rs370243877), leading to amino acid replacement at position 33 of the protein (p.Asp33Val, NM-018129.3, mutation frequency in the ExAC control sample 0.0235%); as probably pathogenic - a previously undescribed heterozygous mutation in intron 3 of the PNPO gene (chr17:46022086G>A, rs766037058), leading to disruption of the splicing site and synthesis of the full-length protein (c.363+5G>A, NM_018129.3, OMIM: 610090, the value of the algorithm for predicting its influence on the function of AdaBoost splicing sites is 1.000).

A heterozygous mutation was also found in exon 4 of the EARS2 gene (chr16:23546678A>T), leading to a premature translation termination site at codon 163 (p.Tyr163Ter, NM_001083614.1). Such mutations have been described in patients with combined oxidative phosphorylation deficiency type 12 (OMIM: 614924). In this case (when no second mutation in the gene is detected), the result is regarded as an option with uncertain clinical significance, however, the mutation may be related to the phenotype. The parents did not undergo a genetic examination.

Prescribed treatment was: pyridoxine hydrochloride intramuscularly, then - pyridoxal phosphate at the rate of 10-50 mg / kg /day. On the 7th day after the start of treatment, the patient's consciousness was assessed as clear, she was able to sit up independently and stand with support. Her seizures stopped, appetite improved, during rehabilitation positive dynamics in neuropsychic development was noted with an expansion of the range of motor activity, the appearance of gaming activity, emotions and attempts to pronounce individual sounds.

At the age of 5 years 1 month there was a new epileptic seizure. The dose of pyridoxal phosphate was increased to 600 mg/day, convulsive attacks stopped. Concomitant diseases at age 5 were perianal dermatitis, vulvitis, continuously recurrent leukocyturia. Subsequent courses of medical rehabilitation was prescribed with positive dynamics.

In 2019, hyperkinesis (blinking), tremor, restlessness reappeared; in the summer were tonic-clonic seizures with vocalization, lasting 15-20 minutes and the status course of an attack, operculations, loss of appetite. By the end of the year, there was constant nausea and a gag reflex at the sight of food, vomiting with yellow mucus and a sour smell once every 5-7 days, accompanied by febrile fever, the smell of "rotten cheese" from the scalp and excrements during attacks. Motor clonic seizures appeared with a frequency of once every 1-2 months, symmetrical chill-like tremor - up to 3-5 times a day. Periodic episodes of psychomotor agitation, stereotyped movements were also noted.

Neurological status. There are bradypsychia, delayed psycho-motor development, coordination disorder. Patient does not pronounce words, speech is active only during the game-vocalisms, self-service skills are not formed. Autism spectrum disorders with general speech underdevelopment of level 1, psychomotor alalia were noted. Cerebral, meningeal symptoms are negative. The gait is uncertain. Cerebellar tests are negative. Cranial nerves: palpebral fissures D=S, pupils D=S, pupil reaction to light: direct D=S, consensual D=S. The volume of movement of the eyeballs is complete D=S, there is no nystagmus. The face is symmetrical D=S. There is no language deviation. Swallowing, phonation are not disturbed. Muscle tone: arms - reduced D=S, legs - normal D=S. Tendon reflexes: from the arms and legs increased D=S. There are no pathological foot signs, pelvic functions are preserved. Patient shows signs of slightly asymmetrical (with an accent on the left) motor awkwardness, reduced nutrition (Body weight 21,5 kg).

Results of instrumental and laboratory studies. The following disorders were detected on the EEG prior to the start of etiological therapy: Epileptiform activity in the form of "peak-wave" complexes in the frontal and central-temporal leads, more on the right; slowing down of activity in the temporal zone.

In the biochemical analysis of blood the level of amino acids (µmol/l) is low: alanine 119.30; glutamic acid 72.00; glycine 86.50; ornithine 22.10; proline 87.00. Activity of alanine aminotransferase is 24.9 U/l (reference values 0-29 U/l), aspartate aminotransferase - 26.4 U/l (reference values 0-48 U/l).

 Control visit. After the diagnosis was verified by exome sequencing, the patient was prescribed etiotropic therapy: pyridoxal phosphate 300 mg/day. The pre-elevated (1070 nmol/l) plasma concentration of vitamin B6 (pyridoxal-5-phosphate) normalized. EEG data - video monitoring showed moderately severe violations of BEA of the brain; the main rhythm is formed by age; registered regional slowing of the rhythm in the right central-parietal region. Epileptiform activity, clinical paroxysms, EEG patterns of epileptic seizures were not registered.

Final diagnosis: Genetic focal epilepsy due to a mutation in the PNPO gene (chr17: 46019139A> T, rs370243877). The type of attack is focal with impaired consciousness. PNPO developmental and epileptic encephalopathy. Cognitive impairment. Alalia. Motor awkwardness.

Psychological status. Diagnostics of cognitive activity showed that the girl is accessible to contact; she does not speak and comprehension of the speech is shown only in the form of understanding simple commands and simple instructions for the task. The child's object-sensory activity is carried out 100% through visual perception and shape perception, the perception of size is developed by 50%, spatial perception - 12%, color perception is completely absent. The insufficiency of these afferentations is a consequence of the decrease in the “zone of actual development”, which may be attributed to pedagogical neglect. In the motor sphere, gross motor skills are fully formed, fine motor skills are developed by 54%, objective activity is formed by 9%, taking into account the skills of game and constructive praxis, speech function is developed by 25%, self-service skills - by 60%, socialization – by 40%. Psychological diagnostics of the state of higher mental functions was carried out by depicting the structural and functional features of the brain, as a result of which topical insufficiency of brain areas was revealed. Figure 1 shows the level of formation of brain zones.

Figure 1: The degree of formation of brain departments that implement sensory and motor skills.

Despite the pronounced cognitive deficit in the child, the implementation of the program of psychological rehabilitation may expand the "zone of actual development" in the structure of the sensory, subject and pedagogical profile (since there are preserved components of cognitive activity)

DISCUSSION

Patient’s clinical diagnosis was established only at the age of 5 years, based on clinical manifestations and exome sequencing. The primal reduction of the dose of pyridoxal-5'-phosphate provoked a relapse of status epilepticus and a regression of acquired cognitive skills. A subsequent increase of treatment in combination with dietary therapy provided an unstable clinical remission without further improvement in the patient's condition. Such a response to the therapy has also been demonstrated in other studies [6,7].

Although in patients with a typical course of the disease, there is a several-fold increase in the level of glycine and glutamic acid in the blood plasma [1,5–7,9], in our case there is a decrease in glycine to 86,50 µmol/l (norm: 100-400 µmol /l) and other amino acids. Hypoglycinemia is an extremely rare condition, it occurs only in severe hereditary aminoacidopathy, but in our patient, tandem mass spectrometry was performed twice (including against the background of an attack) in 2016 and did not show any data of hereditary aminoacidopathy, organic aciduria, defects β-oxidation of fatty acids. The girl has a positive reaction to the oral intake of amino acid complexes and glycine separately, therefore, additional genetic analysis can be performed for 3-phosphoglycerate dehydrogenase deficiency, the clinical manifestations of which may be encephalopathy and seizures unresponsive to anticonvulsants [10]. Symptoms of this disease can be stopped by joint intake of serine and glycine so this diet may be developed for our patient. The study of vitamin B6 metabolites in de novo serine biosynthesis by Ramos et al (2017) had one group of rats which received a pyridoxine-deficient diet, while the diet of the control group of rats contained a normal amount of pyridoxine. This study has demonstrated a decrease in serine biosynthesis in Neuro-2a cells in vitamin B6 deficient rats. The pyridoxal-5'-phosphate-dependent enzyme phosphoserine aminotransferase (PSAT, EC 2.6.1.52) cannot function fully in conditions of vitamin B6 deficiency, and likely reduces the synthesis of phosphoserine and serine in animals on a pyridoxine-deficient diet. The production of glycine depends on the availability of serine and on the pyridoxal-5'-phosphate-dependent enzyme SHMT, which catalyzes part of the transformation of glycine, and the simultaneous deficiency of serine and pyridoxal-5'-phosphate can reduce its activity and lead to a decrease in the content of glycine in blood plasma [9].

Some authors reported EEG changes in patients with pyridoxine-dependent epilepsy [11]. In our patient, no clear epileptiform activity was registered either before or after the start of treatment with pyridoxal-5'-phosphate; this variant of EEG was also described by other researchers [5,6]. Changes in the brain during magnetic resonance imaging in patients with pyridoxine-dependent epilepsy may vary from normal to diffuse atrophy of the gray and white matter of the hemispheres [2]; in our case no changes were detected.

According to Plecko B. Et al., with late diagnosis stable remission after the appointment of pyridoxal-5'-phosphate is observed only in a few patients [1]. Early treatment is critical to prevent irreversible damage to the central nervous system and shows positive results [1,5,6]. Patients with pyridoxine-dependent epilepsy require lifelong supplementation with pyridoxal-5'-phosphate. Therapeutic doses of the drug vary from 15 to 30 mg/kg/day [1]. The daily requirement for vitamin B6 in infancy is 0.1–0.3 mg. Pyridoxal-5'-phosphate doses up to 500 mg/day are considered safe in children with classical vitamin B6 deficiency, but higher doses may cause reversible sensory and rare motor neuropathy [1], so total daily doses of pyridoxal-5'-phosphate, should not exceed 200-300 mg. There are no data on the optimal dose of the vitamin for long-term treatment. In experimental animals, doses of pyridoxal 5'-phosphate >50mg/kg/d induce ataxia, peripheral neuropathy, and muscle weakness; histological examination demonstrates neuronal damage with loss of myelin and degeneration of sensory fibers in peripheral nerves, dorsal columns of the spinal cord, and descending tract of the trigeminal nerve. In most cases of peripheral neuropathy, the total dose of pyridoxal 5'-phosphate is >1000 mg/day. Some children who take high concentrations of pyridoxal-5'-phosphate develop a persistent increase in transaminases with progression to cirrhosis and hepatocellular carcinoma [3]. To avoid side effects, a fixed effective dose should be used. However, studies showed that daily doses up to 1100 mg/day and 50 mg/kg/day to achieve a state without epileptic seizures did not cause any side effects when they were divided into 4–5 doses per day [12]. In our case the doses of pyridoxal-5'-phosphate less than 600 mg/day induces epileptic seizures and cognitive disfunction. Some mutations in the genes encoding of pyridoxamine-5-phosphate oxidase may require the combined treatment with pyridoxal-5'-phosphate and pyridoxine [12,13]. It is possible that such treatment will have a positive response in our patient as well.

Another interesting feature of this clinical case is an intolerance of the patient to many products: remission occurs only on a low-protein, low-fat diet with the exclusion of dairy, meat products and eggs. Similar dietary restrictions are observed in ALDH7A1 deficiency (antiquitin deficiency), which often accompanies PNPO gene mutation. In our case ALDH7A1 deficiency was excluded by exome sequencing [13,14]. However, a lysine-restricted diet can also be effective for homozygous mutations in the PNPO gene in some patients [14]. As an example of a diet, the recommendations of Koelker and Ross on glutaric aciduria type I can be used [15].

The patient also has a high content of vitamin B6 in plasma (775.0 nmol/l), which is typical response to an intake of pyridoxal-5'-phosphate (described levels of vitamin B6 in plasma: 400 nmol/l, 1060 nmol /l and 624 nmol/l) [12,18]. It is not known why some patients continue to have seizures even when taking high doses of pyridoxal-5'-phosphate, while others grow almost normally [1,7,19]. The long-term prognosis for this patient remains unclear. For our patient a clarifying genetic study with modification of pharmacological treatment and diet is required, considering that the girl does not tolerate protein hydrolysates and an unstable clinical remission only on a low-protein low-fat diet with the exclusion of dairy, meat products and eggs.

CONCLUSIONS

DNA diagnostics using the method of sequencing of exome regions of the genome is a key method for early verification of the diagnosis of epilepsy in newborns and young children, which in combination with the therapy can improve the prognosis.

The presence of heterozygous mutations in this clinical case suggests other metabolic deficits, which complicates the selection of treatment and requires additional examination of the exome.

To ensure stable remission, nutritional correction is required to compensate for deficient conditions during severe elimination measures, as well as the selection of the minimum sufficient dosage of pyridoxal-5'-phosphate in combination with pyridoxine hydrochloride.

Topical neuropsychological diagnostics and psychological correction based on intact higher mental functions makes the recovery of the patient possible.

Conflict of Interest: The authors of this article have confirmed that there are no conflicts of interest or financial support to report.

For more information: https://jmedcasereportsimages.org/about-us/

For more submission : https://jmedcasereportsimages.org/